Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma

Journal of Clinical Oncology

Volumn 26, Issue 14, 2008, Pages 2406-2408

  Krishnan, Ganapathy ^a   D'Silva, Karl ^a   Al Janadi, Anas ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; RASBURICASE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; COLON CARCINOMA; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HUMAN; HYPERURICEMIA; KIDNEY INJURY; LIVER BIOPSY; METASTASIS; OBSTRUCTIVE JAUNDICE; PLEURA EFFUSION; PRIORITY JOURNAL; TUMOR BIOPSY; TUMOR LYSIS SYNDROME; ULTRASOUND; ADENOCARCINOMA; COLON TUMOR; LIVER TUMOR; MALE; MIDDLE AGED; PATHOLOGY;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TUMOR LYSIS SYNDROME;

EID: 44249085911     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.7603     Document Type: Article

References (13)

1. Cairo MS, Bishop M: Tumour lysis syndrome: New therapeutic strategies and classification. Br J Haematol 127:3-11, 2004
2. Vora A, Bhutani M, Sharma A, et al: Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase. Ann Oncol 13:1833-1834, 2002
3. Pou M, Saval N, Vera M, et al: Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 44:1239-1241, 2003
4. Ali R, Ozkalemkas F, Ozkan A, et al: Tumour lysis syndrome with acute renal failure during imatinib therapy. Leuk Res 31:573-574, 2007
5. Abou Mourad Y, Taher A, Shamseddine A: Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20. Hematol J 4:222-224, 2003
6. Saylor PJ, Reid TR: Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. J Clin Oncol 25:3544-3546, 2007
7. Sezer O, Vesole DH, Singhal S, et al: Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma 7:233-235, 2006
8. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
9. Lenz HJ, Gold PJ, Mirtsching B, et al: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. J Clin Oncol 23:248s, 2004 (suppl; abstr 3510)
10. Lenz HJ, Mirtsching B, Cohn AL, et al: Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol 24:255s, 2005 (suppl; abstr 3536)
11. Saltz LB, Meropol NJ, Loehrer PJ, Sr, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004
12. Diaz Rubio E, Tabernero J, van Cutsem E, et al: Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer. An international phase II study. J Clin Oncol 23:254s, 2005 (suppl; abstr 3535)
13. Rougier P, Raoul JL, Van Laethem JL, et al: Cetuximab + FOLFIRI as first-line treatment for metastatic colorectal CA. J Clin Oncol 22:248s, 2004 (suppl; abstr 3513)